Achilles Therapeutics
A UK-based developer of personalized T-cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system.
In September 2019, the company closed a £100 million ($120.6 million) Series B financing led by incoming US investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.
Proceeds from this financing, which was over-subscribed, will deliver two human proof-of-concept studies in non-small cell lung cancer and melanoma.
Latest Achilles Therapeutics News & Features
19 November 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze